Aldeyra Intends to Submit FDA Formal Dispute Request for Reproxalap; Cash Runway Extended into 2029

Aldeyra intends to submit a Formal Dispute Resolution Request to the FDA appealing the March 16, 2026 Complete Response Letter for reproxalap and reports operational cash runway extended into 2029.Key Highlights:Original SEC Filing: Aldeyra Therapeutics, Inc. [ ALDX ] - 8-K - Sep. 29, 2026This is a…